The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help ...

Researchers at the University of Colorado Anschutz Medical Campus have identified LL-341070, a promising drug candidate that ...

The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Jan 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's ...